Do you have asthma and Allergic Bronchopulmonary Aspergillosis?
By Lauren Amphlett

We’re excited to share that there’s a new clinical study that’s looking into an innovative treatment specifically for individuals dealing with both asthma and ABPA. This treatment comes in the form of an inhaler called PUR1900.

What is PUR1900?

PUR1900 is an inhaled medication that’s being tested for its effectiveness against the symptoms of ABPA in asthma patients. It’s designed to deliver an antifungal medication directly to the lungs, where it can work right at the source of the problem.

The Study at a Glance

The study spans several months and is divided into three key phases:

  1. Screening Period (28 days): Researchers will do some tests to make sure this study is the right fit for you.
  2. Treatment Period (112 days): If you’re eligible, you’ll use the inhaler for about 16 weeks. You could receive either a higher dose, a lower dose of PUR1900, or a placebo (which doesn’t contain the actual medication).
  3. Observation Period (56 days): After the treatment, researchers will keep an eye on your health for another 8 weeks.

What Will Participants Do?

  • Daily Routines: You’ll use the inhaler daily as directed and keep track of your experience in an electronic diary (eDiary).
  • At-Home Checks: You’ll measure your breathing strength daily using a simple device.
  • Clinic Visits: Approximately once a month, you’ll visit the clinic for check-ups and tests.

Why Participate?

By joining this study, you’re not only potentially finding a new way to manage your asthma and ABPA, but you’re also contributing to medical research that could help countless others in the future.

Safety and Benefits

Your safety is the top priority. You’ll be closely monitored throughout the study, and all treatments will be provided at no cost to you. Plus, if you successfully complete the study, there may be an opportunity to continue receiving PUR1900 in a follow-up study.

Taking the Next Step

Researchers are looking for adults with asthma and ABPA who are interested in exploring this new treatment option. If you’re ready to take the next step, eligibility and contact details on how you can participate in this groundbreaking study can be found by clicking here.